PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1901523
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1901523
Anemia Supplements Market size was valued at US$ 1,897.89 Million in 2024, expanding at a CAGR of 8.5% from 2025 to 2032.
The Anemia Supplements Market is the industry that produces and distributes nutritional supplements designed to prevent or treat anemia by increasing levels of iron, vitamin B12, folic acid, and other essential micronutrients. These supplements are used by people who have dietary deficiencies, chronic conditions, or high physiological requirements. The rising global prevalence of anemia, particularly among women and children, as well as increased awareness of preventive healthcare, are driving market growth. Key market trends are the shift toward personalized and targeted supplementation, which is aided by digital health tools and at-home diagnostic kits. However, the market is limited by side effects associated with iron supplements, such as gastrointestinal discomfort, which can reduce adherence. Despite this, there are significant opportunities for developing novel, gentle, and high-bioavailability formulations such as liposomal iron, plant-based blends, and combination supplements tailored to specific anemia types, which will support strong future market growth.
Anemia Supplements Market- Market Dynamics
Rising demand for personalized medicine drives growth in the anaemia supplements market.
The growing demand for personalized medicine is driving the growth of the anemia supplement market. Supplement formulations are becoming more targeted as consumers and healthcare providers adopt individualized treatment approaches based on genetic profiles, nutrient deficiencies, and specific anemia types. Personalized nutrition allows for tailored combinations of iron, vitamin B12, folic acid, and other micronutrients, resulting in more effective outcomes while reducing side effects. This shift is consistent with broader healthcare trends, in which precision-based interventions are gaining regulatory momentum. For instance, in March 2023, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately12 of them are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Such advancements reflect the growing acceptance of targeted therapies, resulting in increased demand for personalized anemia supplements.
The Global Anemia Supplements Market is segmented by Application, Form, Product, Distribution Channel and Region.
According to the Application, Iron-deficiency anemia (IDA) has a sizable market share, around 45%, because it is the most common anemia type and a widespread nutritional deficiency. For example, the WHO estimates that 30% of the global population suffers from this condition, resulting in a constant demand for therapeutic solutions such as the use of intravenous (IV) iron infusions and the development of new oral formulations. In addition, drugs such as ferric carboxymaltose have gained popularity due to their ability to rapidly replenish iron stores with a limited number of infusions, giving them an advantage over traditional oral supplements, which frequently have poor patient compliance due to gastrointestinal side effects. Thus, there is an opportunity to expand the use of these advanced therapies, such as for the treatment of iron deficiency in patients with chronic conditions like CKD, where oral iron drugs are frequently ineffective. These advancements, combined with growing awareness programs in developing countries, contribute to the ongoing focus on treating IDA. As a result, IDA's market leadership and continued growth are established.
By product, the ferrous fumarate segment holds the prominent share in 2025, owing to its high elemental iron content, favorable absorption profile, and cost-effectiveness compared to alternative formulations. Its widespread use in prescription and over-the-counter supplements, backed up by strong clinical evidence for treating iron-deficiency anemia, has hastened its spread. Furthermore, its availability in tablets, capsules, and fortified foods has resulted in widespread market penetration. For example, in January 2024, Dr. Reddy's acquired MenoLabs to broaden its portfolio of women's health and nutritional supplements. This acquisition increased its emphasis on iron-deficiency-related products, with ferrous fumarate remaining one of the most widely used and clinically preferred iron salts.
Anemia Supplements Market- Geographical Insights
North America holds a significant share of the Anemia Supplements Market, due to high healthcare spending, strong consumer awareness, and widespread nutritional screening. The region's large population with anemia, caused by conditions such as chronic kidney disease (CKD), cancer, and gastrointestinal disorders, creates a steady demand for iron, vitamin B12, and folate supplements. Easy access to pharmacies, established retail and e-commerce channels, and the presence of major nutraceutical manufacturers all contribute to market growth. Additionally, preventive health trends and physician recommendations for dietary supplementation are driving up adoption of non-prescription anemia treatments.
For instance, the CDC estimates that more than 35 million people in the United States will have CKD in 2023, with many requiring ongoing nutritional support such as iron and B-vitamin supplements to manage anemia risk. Strong insurance coverage for diagnostic testing and early detection practices also increases supplement use throughout North America.
United States Anemia Supplements Market- Country Insights
The U.S. anemia supplements market is a major contributor to North America due to the high prevalence of iron-deficiency anemia, growing awareness of nutritional health, and the widespread availability of iron, vitamin B12, folate, and multinutrient supplements across pharmacies, supermarkets, and online platforms. The growing popularity of personalised nutrition, aided by home blood-testing kits and digital health apps, is driving up demand for targeted supplements. Women, children, and the elderly, all of whom are at a higher risk of anemia, drive consistent demand. Although prescription anemia drugs dominate clinical care, a strong healthcare infrastructure and regular diagnostic screening indirectly support the supplements market by detecting deficiencies early.
For example, the drug Reblozyl (luspatercept), which was approved for anemia in MDS patients, earned more than USD425 million in U.S. sales in a single quarter of 2024. As a result, due to a strong pharmaceutical pipeline, advanced healthcare infrastructure, and persistent anemia cases, North America continues to dominate the Anemia Drugs Industry, a trend that is expected to continue until 2030.
The competitive landscape of the anemia supplements market is characterized by the presence of several key players, each attempting to strengthen their market position through strategic initiatives such as mergers and acquisitions, partnerships, and new product development. These companies invest heavily in R&D to innovate and introduce advanced treatment options that meet the diverse needs of anemia patients. The emphasis on personalized medicine and targeted therapies is fueling competition, with companies attempting to distinguish their products based on efficacy, safety, and patient outcomes. The entry of new players and the expansion of existing companies into emerging markets add to the competitive environment.
In June 2025, Wanbury Limited launched Wanbury Cred, a new iron supplement designed to address the widespread prevalence of iron deficiency and anaemia, as part of a strategic expansion of its nutritional healthcare portfolio.
In November 2024, Cadila Pharmaceuticals introduced Militol, an advanced iron supplement designed to deliver an optimized blend of nutrients that improve iron absorption and gastrointestinal tolerance, thereby effectively managing iron deficiency.